Global Congress on Pharmacology and Therapeutics October 07-08 2019 Paris, France

M.D., Medical Doctor/ Physician, graduated from Tehran university, School of Medicine with honor. He studied in neurosurgery ward and graduated with a score with thesis on Meningioma Brain Tumour during 6 years. With continuing my practice with special consideration on psychosomatic disorders, He completed many post graduate courses on health psychology, addiction medicine, sexual disorders therapy successfully. He passed many post graduate courses in Neuro, approved by Medical Sciences University. As well, He have been passed post graduate courses on Nutrition, Gastroenterology and herpetology, Obesity treatment and diabetes approved by Tehran University of Medical sciences. He is director of fatty liver and related metabolic disorders study among Iranian families since 2015 and currently publishing the results of our study and research about fatty liver and hyperlipidaemia, diabetes and nutrition as study director and clinician associate member of Iran Hepatitis Network. I am reviewer and associate editor of Hepatitis Monthly Journal and reviewer of journal of Clinical and Translational Herpetology. He is editorial board member of International Journal of Psychology and Neurosciences. He certified graduate, verified reviewer and certified mentor of Publons academy in the field of Clinical Medicine and Herpetology.

Published article in Metabolic disease pharmacology high indexed journal

Mr. Sinha received his Bachelors of Science (BS) and Master of Science (MS) degrees in Bacteriology / Natural Science from the University of Wisconsin – Madison, Wisconsin, USA. He completed his Master’s in Business Administration (MBA) from the New York Institute of Technology, New York, USA. Kuntal Sinha has been in the Pharmaceutical industry for over 25 years. His experience over the years have spanned within the Contract Research Organization (CRO) and pharmaceutical companies. At Covance, Mr. Sinha’s responsibility included research supporting Metabolic Chemistry and Drug Metabolism Since 2016, Mr. Sinha has been managing the activities associated with pharmacovigilance and clinical trial safety and serves as an advisory / consultative capacity in compliance related safety matters. More recently, Mr. Sinha is Director at Alkermes within Clinical Quality Assurance group supporting pharmacovigilance, Medical Affairs and Commercial Organization on drug safety related to adverse events and product complaints.

Clinical Trails

Physician with more than 20 years of experience in clinical development and pharmacovigilance. After working for several years as Vice President and Global Head of drug safety & risk management for Lupin, she founded Clinexel Life Sciences Pvt Limited, that provides consulting and operations services to pharma companies. Deepa has rich experience in conceptualizing innovative products, developing efficient 505b(2) clinic- regulatory strategies for biosimilar and hybrid applications. She was a key member for clinical development and safety monitoring of biosimilars & NCEs in 3 companies. She participated in regulatory meetings with FDA, EMA, rapporteurs and CHMP to discuss the clinical development plans, risk management plans, post marketing data collection required for hybrid applications and requirements of post marketing studies. She has successfully led a consortium of leading generic companies including Teva, Lupin, Sandoz, Alvogen, Mylan, Generis and Gedeon Richter in Europe to conduct post authorization clinical studies imposed as a condition of marketing authorization for a generic product. After successfully completing these studies, results were published in peer reviewed journals.

Pharmacovigilance